Get The App!
Loading the player...
PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks
Share by Email
Send to social websites
Report this video as inappropriate
You can report this video if you think it to be inappropriate, we will review your submission soon. If your reason is not listed here, like copyright infringements, please contact us directly by email.
Select your reason
Violent or Repulsive Content
Hateful or Abusive Content
Harmful Dangerous Acts
At ASH 2015, Dr. Srdan Verstovsek from MD Anderson Cancer Center discusses his abstract titled "PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks."
Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Clinical Outcomes from...
A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with MDS
Safe and Effective Use of Rivaroxaban for Treatment of Cancer-Associated Venous Thromboembolic Disea...
HRQoL and Efficacy with Myelofibrosis Patients in the Phase III Persist-1 Trial of Pacritinib Vs BAT
Quizartinib Significantly Improves Overall Survival in FLT3-ITD Positive AML Patients Relapsed after...
Validation of International Working Group Response Criteria in Higher-Risk MDS
Somatic Gene Mutations Serve As Molecular Biomarkers Predictive for Response to Immunosuppressive Th...
Mechanisms of Resistance to 5-Azacytidine/Decitabine in MDS-AML and Pre-Clinical In Vivo Proof of Pr...
Copyright 2020 by NSCI Group, Inc.
On The Go
About MedEd On The Go